RU2019131252A - Пептидные вакцины на основе pd1 человека и их применение - Google Patents

Пептидные вакцины на основе pd1 человека и их применение Download PDF

Info

Publication number
RU2019131252A
RU2019131252A RU2019131252A RU2019131252A RU2019131252A RU 2019131252 A RU2019131252 A RU 2019131252A RU 2019131252 A RU2019131252 A RU 2019131252A RU 2019131252 A RU2019131252 A RU 2019131252A RU 2019131252 A RU2019131252 A RU 2019131252A
Authority
RU
Russia
Prior art keywords
seq
cancer
peptide
epitope
synthetic
Prior art date
Application number
RU2019131252A
Other languages
English (en)
Russian (ru)
Other versions
RU2019131252A3 (cg-RX-API-DMAC7.html
Inventor
Правин Т.П. КАУМАЯ
Таниос БЕКАЙИ-СААБ
Original Assignee
Огайо Стейт Инновейшн Фаундейшн
Майо Фаундейшн Фо Медикал Эдьюкейшн Энд Рисёрч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Огайо Стейт Инновейшн Фаундейшн, Майо Фаундейшн Фо Медикал Эдьюкейшн Энд Рисёрч filed Critical Огайо Стейт Инновейшн Фаундейшн
Publication of RU2019131252A publication Critical patent/RU2019131252A/ru
Publication of RU2019131252A3 publication Critical patent/RU2019131252A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2019131252A 2017-03-28 2018-03-28 Пептидные вакцины на основе pd1 человека и их применение RU2019131252A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477895P 2017-03-28 2017-03-28
US62/477,895 2017-03-28
PCT/US2018/024831 WO2018183488A1 (en) 2017-03-28 2018-03-28 Human pd1 peptide vaccines and uses thereof

Publications (2)

Publication Number Publication Date
RU2019131252A true RU2019131252A (ru) 2021-04-28
RU2019131252A3 RU2019131252A3 (cg-RX-API-DMAC7.html) 2021-06-01

Family

ID=63678120

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019131252A RU2019131252A (ru) 2017-03-28 2018-03-28 Пептидные вакцины на основе pd1 человека и их применение

Country Status (11)

Country Link
US (1) US11684660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600398B1 (cg-RX-API-DMAC7.html)
JP (1) JP7346302B2 (cg-RX-API-DMAC7.html)
KR (1) KR102653567B1 (cg-RX-API-DMAC7.html)
CN (2) CN110636855B (cg-RX-API-DMAC7.html)
AU (2) AU2018243920B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2963635T3 (cg-RX-API-DMAC7.html)
RU (1) RU2019131252A (cg-RX-API-DMAC7.html)
WO (1) WO2018183488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドImugene Limited ワクチン組成物およびその使用
WO2020071869A1 (ko) * 2018-10-05 2020-04-09 알엔에이진 주식회사 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2023205796A2 (en) * 2022-04-21 2023-10-26 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) * 2023-04-05 2024-10-10 Ohio State Innovation Foundation Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC7.html) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
CN1215404A (zh) * 1996-04-03 1999-04-28 佩普里瑟奇公司 非树状骨架肽载体
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
CA2534060C (en) * 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1912680B1 (en) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2010011315A2 (en) * 2008-07-25 2010-01-28 Viral Genetics, Inc. Proteins for use in diagnosing and treating infection and disease
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014161509A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
TWI676636B (zh) * 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
TWI720946B (zh) 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
CA2971734C (en) * 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies

Also Published As

Publication number Publication date
US11684660B2 (en) 2023-06-27
RU2019131252A3 (cg-RX-API-DMAC7.html) 2021-06-01
KR102653567B1 (ko) 2024-04-02
EP3600398A1 (en) 2020-02-05
WO2018183488A1 (en) 2018-10-04
CN110636855A (zh) 2019-12-31
CN118909082A (zh) 2024-11-08
CN110636855B (zh) 2024-08-09
KR20190137826A (ko) 2019-12-11
ES2963635T3 (es) 2024-04-01
AU2025201760A1 (en) 2025-05-22
JP7346302B2 (ja) 2023-09-19
AU2018243920B2 (en) 2024-12-12
EP3600398B1 (en) 2023-09-13
US20200197498A1 (en) 2020-06-25
BR112019020386A2 (pt) 2020-06-09
EP3600398A4 (en) 2020-12-30
CA3058393A1 (en) 2018-10-04
AU2018243920A1 (en) 2019-10-31
JP2020512375A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
JP2020512375A5 (cg-RX-API-DMAC7.html)
AU2020263231B2 (en) Camptothecin derivatives
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
AU2020227006B2 (en) Cytotoxic benzodiazepine derivatives
CN111295389A (zh) 生物活性物偶联物及其制备方法和用途
JP6272230B2 (ja) 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
TWI874262B (zh) 抗her3抗體-藥物結合物之用途
HRP20230542T1 (hr) T stanični receptori
RU2009149462A (ru) АНТИТЕЛА ПРОТИВ NRR Notch1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HRP20221021T1 (hr) T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02
JP2019506841A5 (cg-RX-API-DMAC7.html)
JP2025508009A5 (cg-RX-API-DMAC7.html)
TW202146057A (zh) 半胱胺酸工程改造抗體之結合物
JP2014166186A5 (cg-RX-API-DMAC7.html)
TWI827575B (zh) 苯二氮平衍生物
JP2019502650A5 (ja) 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
RU2018104266A (ru) Полилигандные лекарственные конъюгаты и их применения
RU2013126494A (ru) АНТИТЕЛА ПРОТИВ Notch1
JP2016518351A5 (cg-RX-API-DMAC7.html)
CA3160466A1 (en) Dual il-2r and il-7r binding compounds
TW202535885A (zh) 配體-藥物偶聯物、偶聯連接子及其用途
JP2015530989A5 (cg-RX-API-DMAC7.html)
JP2022548364A5 (cg-RX-API-DMAC7.html)
ES2321114T3 (es) Camptotecinas conjugadas en posicion 7 con peptidos ciclicos como agentes citostacios.
KR20250136340A (ko) 링커 약물 및 이의 항체-약물 접합체의 제조 방법과 응용